Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" google.com

Myelofibrosis Market to Double by 2034, Surpassing USD 5.6

google.com·13w

Five Under 5: Top Oncology Videos for the Week of 2/8

google.com·13w

Incyte's weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns (Feb 10)

google.com·13w

Karyopharm investors fasten their seatbelts | ApexOnco

google.com·13w

Selective JAK Inhibition in RA vs PV

google.com·13w

Karyopharm Therapeutics Inc. SEC 10-K Report

google.com·13w

Karyopharm signals $130M–$150M revenue target for 2026 with pivotal myelofibrosis data ...

google.com·13w

Karyopharm Therapeutics Q4 Earnings Call Highlights

google.com·13w

Karyopharm Therapeutics Inc. Q4 2025 Earnings Call Summary

google.com·14w

Karyopharm (KPTI) Q4 2025 Earnings Call Transcript

google.com·14w

KPTI: 2025 revenue rose, costs fell, and key myelofibrosis trial data is due in March

google.com·14w

Karyopharm Q4 2025 slides: Revenue growth amid pivotal myelofibrosis readout preparations

google.com·14w

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights ...

google.com·14w

Repurposed Drug Shows Promise for Essential Thrombocythemia Treatment

google.com·14w

Active Biotech Year End Report 2025

google.com·14w

Galecto prices $275 million stock offering at $19 per share

google.com·14w

FDA Clears Protocol Update for Tasquinimod in Myelofibrosis Trial

google.com·14w

PharmaEssentia Shores up Supply with $46M Investment in Puerto Rico Plant

google.com·14w

Hema Now: Advancing Care in Myelofibrosis - European Medical Journal

google.com·14w

Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal ...

google.com·14w

Log in to enable infinite scrolling